Dermata Therapeutics, Inc.

NasdaqCM:DRMA Stock Report

Market Cap: US$4.9m

Dermata Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqCM:DRMA Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
27 May 26BuyUS$250,000Kyri Van HooseIndividual122,549US$2.04
17 Feb 26BuyUS$1,270Maria Bedoya-ToroIndividual1,000US$1.27

Insider Trading Volume

Insider Buying: DRMA insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of DRMA?
Owner TypeNumber of SharesOwnership Percentage
Private Companies8,0950.201%
Institutions235,3025.85%
Individual Insiders845,05921%
General Public2,933,68772.9%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 530.6%.

Top Shareholders

Top 20 shareholders own 27.07% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
17.2%
Gerald Proehl
692,802US$838.3k-0.01%no data
3.27%
Kyri Van Hoose
131,380US$159.0k0.73%no data
1.87%
Bigger Capital, LLC
75,200US$91.0k-68.6%0.45%
1.34%
Armistice Capital LLC
53,910US$65.2k0%no data
1.2%
Geode Capital Management, LLC
48,334US$58.5k1,670%no data
0.89%
UBS Asset Management AG
35,608US$43.1k2,780%no data
0.5%
Welch & Forbes LLC
20,000US$24.2k0%no data
0.49%
Mary Fisher
19,695US$23.8k0%no data
0.2%
Hale BioPharma Ventures LLC
8,095US$9.8k0%no data
0.043%
MCF Advisors, LLC
1,732US$2.1k0%no data
0.026%
Maria Bedoya-Toro
1,046US$1.3k2,080%no data
0.018%
Tower Research Capital Europe Limited
716US$866.3-64.2%no data
0.0025%
SBI Holdings, Inc.
101US$122.20%no data
0.0017%
David Hale
67US$81.30%no data
0.00065%
Wendell Wierenga
26US$31.60%no data
0.0003%
Kathleen Scott
12US$14.60%no data
0.00027%
Christopher Nardo
11US$13.10%no data
0.00025%
Andrew Sandler
10US$12.20%no data
0.00025%
Brittany Bradrick
10US$12.20%no data
0.00002%
Citigroup Inc.
1US$1.00%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/09 08:03
End of Day Share Price 2026/06/09 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Dermata Therapeutics, Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Anthony VendettiMaxim Group